Genetically Predicted Gut Microbiota and Crohn’s Disease: A Multiscale Mendelian Randomization Study Integrating Colocalization, Drug Target, and Cross-Ancestry Validation
Abstract
Purpose Observational studies report gut dysbiosis in Crohn’s disease (CD), but whether dysbiosis is causal and which host mechanisms mediate it remain unresolved. We aimed to infer causal microbiota-CD relationships, identify host mediators, and nominate therapeutic targets using a multiscale Mendelian randomization (MR) framework. Methods Two-sample and bidirectional MR were applied to MiBioGen microbiota genome-wide association study (GWAS) summary statistics (n = 18,340; 198 testable taxa) and FinnGen R10 CD GWAS (1727 cases/375,000 controls), with Benjamini-Hochberg correction and a priori power analysis. We integrated BMI-adjusted multivariable MR, inflammatory-protein mediation MR, intestinal eQTL colocalization and SMR, protein-protein interaction analysis, drug-target MR, external metagenomic validation, and replication in an independent East Asian CD GWAS (7372 cases/15,456 controls); this prespecified triangulation design offsets the limited size of the European discovery cohort. Results Of 198 taxa, 17 were nominally associated and one survived false-discovery-rate correction. Subdoligranulum was nominally protective in Europeans (OR 0.726, 95% CI 0.529–0.995, P = 0.046), genome-wide significant in East Asians (P = 1.7×10−11), and depleted in independent metagenomes. Colocalization implicated sigmoid-colon PTPRG as a host mediator (PP.H4 = 0.906; SMR P = 0.003), and IL-10 nominally mediated the protective effect (indirect effect −0.207, 95% CI −0.408 to −0.008; proportion 64.7%). Genetically proxied JAK1 inhibition reduced CD risk (OR 0.686, P = 6.3×10−13), whereas TYK2-inhibition proxies raised risk (OR 1.442). Conclusion Convergent but preliminary genetic evidence supports a causal role of gut microbiota in CD, identifies PTPRG as a novel host-microbiota interface gene, and supports JAK1 as a therapeutic target.